[Vaccine therapy in the treatment of nasal and sinus bacterial allergies].
An analysis was performed of the course of nasal and sinus bacterial allergy in 160 children treated in the years 1981-1990 with bacterial vaccines. History data, results of medical examinations and laboratory investigations, indications and contraindications to vaccine therapy, and the methods and results of treatment are presented. Vaccines available in Poland were used--Polyvaccium (nasal and subcutaneous) produced by Biomed, Broncho-Vaxom, IRS-19. As the main criterion of positive results, improvement or regression of clinical manifestations, normalization of immunoglobulin level, and also extinction of organ reactions and generalized and local skin reactions to bacterial allergens, were accepted. Very good and good results were achieved in 63% of the studied patients. The best results were achieved using combined treatment--vaccine therapy, anti-inflammatory drugs, and symptomatic antiallergic treatment (68% of positive results). In comparison to the control group (80 children) in which no vaccine therapy was used, the results obtained in the studied group were statistically significantly better.
Ziuzio
S
S
Klinicznego Oddziału Otolaryngologicznego Wojskowego Szpitala Klinicznego w Bydgoszczy.
Sakson
B
B
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D001419:Bacteria; D002457:Cell Extracts; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D010254:Paranasal Sinus Diseases / Q000628:therapy*; D012852:Sinusitis / Q000628:therapy*; D000095983:Bacterial Lysates
D000276:Adjuvants, Immunologic; D002457:Cell Extracts; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates; C079233:IRS 19
Wakcynoterapia w leczeniu alergii bakteryjnej nosa i zatok.